Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of heparin cofactor II
- 1 June 1994
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 74 (5) , 463-475
- https://doi.org/10.1016/0049-3848(94)90267-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Is heparin the ideal anticoagulant for cardiopulmonary bypass?Thrombosis Research, 1992
- Influence of heparin treatment on biochemical markers of an activation of the coagulation systemThrombosis Research, 1992
- Dermatan sulphate in haemodialysisThe Lancet, 1992
- Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarctionThe American Journal of Cardiology, 1991
- Anticoagulant and fibrinolytic pharmacokinetics of sulodexide in manFibrinolysis, 1990
- Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties.Journal of Clinical Investigation, 1989
- Heparin for Prophylaxis of Venous ThromboembolismAnnals of the New York Academy of Sciences, 1989
- NEED FOR LONG-TERM ANTICOAGULANT TREATMENT IN SYMPTOMATIC CALF-VEIN THROMBOSISThe Lancet, 1985
- The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparinBlood, 1985
- The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factorBritish Journal of Haematology, 1984